期刊文献+

8223例维持性血液透析患者急性并发症的观察及护理 被引量:1

下载PDF
导出
摘要 目的控讨维持性血液透析患者透析过程中出现并发症的原因,对并发症进观察及护理。方法结合临床实际,对血液透析出现的并发症进行具体分析,制定并实施个体化防治措施,有效减少急性并发症的发生。结果血液透析并发症中低血压发生率占6.81%;依次肌肉痉挛占6.69%;高血压占3.82%;心律失常占0.89%;失衡综合征占0.68%;心脏停跳占0.02%;并发症总发生率18.91%。结论护士应有高度的责任心、敏锐的观察力。积极查明原因,针对病因实施个体化防治,降低了患者急性并发症的发生率。
作者 毛艳华
出处 《中国实用医药》 2013年第26期216-217,共2页 China Practical Medicine
  • 相关文献

参考文献4

二级参考文献11

  • 1[1]Ruilope LM,Salvetti A,Jamerson K,et aL Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study[J].J Am Soc Nephrol,2001,12(2):218-225.
  • 2[2]Maschio G,Alberti D,LocateUi F,et aL Angiotensin-converting enzyme inhibitors and kidney protection:the AIPRI triaL The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group[J].J Cardiovasc Pharmacol,1999,33(suppl 1):S16-20.
  • 3[3]Hou FF,Zhang X,Zhang GH,et al.Efficacy and safety of benazepril for advanced chronic renal insufficiency[J].N Engl J Med,2006,354 (2):131-140.
  • 4[4]Ruggenenti P,Pema A,Gherardi G,et aL Renal function and require-ment for dialysis in chronic nephropathy patients on long-term ramipril:REIN follow-up trial.Gruppo Italiano di Studi Epidemiologici in Nefrolo-gia (GISEN)[J].Lancet,1998,352(9136):1252-1256.
  • 5[5]Parring HH,Lehnert H,Brochner MJ,et aL The effect of irbesartan on the development of diabetic ncphropathy in patients with type 2 diabetes[J].N Engl J Med,2001,345(12):870-878.
  • 6[6]Giancarlo V,Nigel MW.Microalbuminuria reduction with valsartan in patients with type-2 diabetes mellitus:a blood pressure-independent effect[J].Circulation,2002,106(3):672-678.
  • 7[7]Lewis EJ,Nunsicker LG,Clarke WR,et aL Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephrcpathy due to type 2 diabetes[J].N Engl J Med,2001,345(12):851-860.
  • 8[8]Brenner BM,Cooper ME,Zecuw D,et al.Effects of losartan on renal and cardiovascular outcomes in patients with type 2diabetes and nephrop-athy[J].New Engl J Meal,2001,345(12):861-869.
  • 9[9]Julius S,Kjeldsen SE,Weber M,et aL Outcomes in hypertensive pa-tients at high cardiovascular risk treated with regimens based on valsrtan or andodipine:the VALUE randomized trial[J].Lancet,2004,363(9426):2022-2031.
  • 10[10]Wachtell K,Dahlof B,Rokkedal J,et aL Change of left ventrieular geo-metric pattern after 1 year of antihypertensive treatment:the Losartan In-tervention For Endpoint reduction in hypertension(LIFE) study[J].J Am Heart,2002,144(6):1057-1064.

共引文献56

同被引文献4

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部